Alios BioPharma Inc.
This article was originally published in Start Up
Executive Summary
Alios BioPharma aims to create an improved version of interferon--the only drug that could be considered a broad-spectrum antiviral--to help patients who do not respond well to currently marketed forms of the protein. Alios also plans to develop a small-molecule drug that can be given orally yet carry out a key function of the interferon response-degrading viral genomes. Such a drug could potentially treat influenza, hepatitis C and B, HIV, and a host of other viruses.
You may also be interested in...
Vertex Prepares For HCV Combo Research By Licensing Two Compounds From Alios
Vertex pays $60 million upfront to license two nucleotide polymerase inhibitors it will test in combination therapy with other HCV assets in its pipeline.
Vertex Prepares For HCV Combo Research By Licensing Two Compounds From Alios
Vertex pays $60 million upfront to license two nucleotide polymerase inhibitors it will test in combination therapy with other HCV assets in its pipeline.
The A-List: 2009's Trend-Shaping Series A Financings
New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. In biopharmaceuticals, corporate venture got in at the ground floor while device start-ups continued to see stronger support from smaller, regional investors than traditional VCs.